- Home
- TOVX vs TCBP Comparison
TOVX vs TCBP Comparison
Compare TOVX & TCBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- TCBP
- Stock Information
- Founded
- TOVX 2001
- TCBP 2013
- Country
- TOVX United States
- TCBP United Kingdom
- Employees
- TOVX N/A
- TCBP N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- TCBP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TOVX Health Care
- TCBP Health Care
- Exchange
- TOVX Nasdaq
- TCBP Nasdaq
- Market Cap
- TOVX 3.1M
- TCBP 3.0M
- IPO Year
- TOVX 2006
- TCBP 2022
- Fundamental
- Price
- TOVX $1.37
- TCBP $0.68
- Analyst Decision
- TOVX Strong Buy
- TCBP
- Analyst Count
- TOVX 1
- TCBP 0
- Target Price
- TOVX $6.00
- TCBP N/A
- AVG Volume (30 Days)
- TOVX 4.8M
- TCBP 3.0M
- Earning Date
- TOVX 11-12-2024
- TCBP 11-29-2024
- Dividend Yield
- TOVX N/A
- TCBP N/A
- EPS Growth
- TOVX N/A
- TCBP N/A
- EPS
- TOVX N/A
- TCBP N/A
- Revenue
- TOVX N/A
- TCBP N/A
- Revenue This Year
- TOVX N/A
- TCBP N/A
- Revenue Next Year
- TOVX N/A
- TCBP N/A
- P/E Ratio
- TOVX N/A
- TCBP N/A
- Revenue Growth
- TOVX N/A
- TCBP N/A
- 52 Week Low
- TOVX $1.24
- TCBP $0.56
- 52 Week High
- TOVX $17.00
- TCBP $138.00
- Technical
- Relative Strength Index (RSI)
- TOVX 37.71
- TCBP 23.01
- Support Level
- TOVX $1.31
- TCBP $1.05
- Resistance Level
- TOVX $2.22
- TCBP $1.25
- Average True Range (ATR)
- TOVX 0.24
- TCBP 0.22
- MACD
- TOVX -0.00
- TCBP 0.06
- Stochastic Oscillator
- TOVX 4.51
- TCBP 10.36
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About TCBP TC BioPharm (Holdings) plc
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.